As per the research conducted by GME, the Global Cardiopulmonary Stress Testing Devices Market will reach USD 6.7 billion from USD 3.7 billion with a CAGR value of 5% from 2021 to 2026. The factors helping the market to grow rapidly include the increasing incidence of heart and lung disorders such as arrhythmia and heart valve imbalance, rapidly changing lifestyle, high incidence of cardiovascular and pulmonary diseases, launch of point of care diagnostic devices, rising global patient population, and launch of FDA approved medical devices